P1.01-108 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.665
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Management of Anesthesia-Related Adverse Events

THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA
2004English

Management of Immune Checkpoint Inhibitor‐related Dermatologic Adverse Events

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2019English

JCSE01.19 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cardiovascular Immune‐related Adverse Events: Evaluation, Diagnosis and Management

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2020English

P3.13-09 ALTER-0303 Study: Tumor Mutation Index (TMI) for Clinical Response to Anlotinib in Advanced NSCLC Patients at 3rd Line

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EL25Management of Immune-Related Adverse Events

Annals of Oncology
MedicineOncologyHematology
2018English

P1.01-17 Immune-Related Adverse Events in Patients With Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Clinical Management of Adverse Events Associated With Lorlatinib

Oncologist
Cancer ResearchMedicineOncology
2019English

Management of Egfr Tki–induced Dermatologic Adverse Events

Current Oncology
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy